SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : ABMD - Replacement Heart System
ABMD 184.23-1.3%2:16 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Lynn7/2/2018 2:47:11 PM
1 Recommendation

Recommended By
lightshipsailor

   of 147
 
Newbie Abiomed edges out Netflix as S&P 500’s top YTD gainer



Jessica Dye in New York
Financial Times
June 29, 2018

Abiomed — which was moved from the S&P MidCap 400 to replace Wyndham Worldwide in the benchmark S&P 500 starting May 31 — has risen 120 per cent in the first six months of the year, according to Thomson Reuters data. Among analysts, Abiomed has five “strong buy” ratings, four “buy”, two “hold” and no sells, with a mean price target of $418.33, according to Thomson Reuters data.

[One has to subscribe to read the rest of the article]

finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext